Oncology Analytics, Inc. Secures $7.5 Million Investment Led by BlueCross BlueShield Venture Partners
PLANTATION, Fla.–(BUSINESS WIRE)–Oncology Analytics, Inc., a URAC-accredited, leading provider of
innovative oncology management services, today announced it has secured
a $7.5 million investment. BlueCross BlueShield Venture Partners led the
investment round with participation from Sandbox Advantage Fund. The
Company will use the investment to broaden new product development,
acquire additional strategic relationships and hire new positions to
rapidly accelerate growth.
Oncology Analytics’ (OA) proprietary system, used in conjunction with an
expert team of board certified clinical oncology specialists, provides
treating physicians with the real-time expertise needed to assure that
patients receive the highest quality of care while eliminating
unnecessary costs. The company enhances patient care by ensuring that
treating providers have the necessary information to deliver the most
efficacious, least toxic and most affordable treatments available to
patients. This assures patients, physicians, and insurers that treatment
choices deliver high quality care and optimal value.
OA has experienced rapid growth and nationwide success in providing
chemotherapy decision support services and is expanding to address all
aspects of cancer care, from screening and diagnosis, to genetic and
specialized testing, optimizing chemotherapy and radiation therapy for
each patient’s individual needs, and for end-of-life care.
“I am delighted about this partnership with BlueCross BlueShield Venture
Partners and Sandbox,” said Dr. Marc Fishman, Chief Executive Officer
and founder of Oncology Analytics. “The additional resources and
expertise will enable OA to continue to expand its services and assure
that all patients receive the highest quality of medical care in
oncology and in other fields of medicine.”
“We are thrilled to have the opportunity to work with Dr. Fishman and
the rest of the Oncology Analytics team to help raise the standard of
care for oncology patients across the country. The collaborative
approach that Oncology Analytics takes has led to great results already.
This is a space where everyone can win – patient, provider and payer,”
said Dr. Thomas Hawes, Managing Director of Sandbox Industries, who
represents BlueCross BlueShield Venture Partners on the Board.
About Oncology Analytics, Inc.
Oncology Analytics, Inc. provides chemotherapy decision support
services, clinical expertise, and physician-centric customer services.
Dr. Marc Fishman founded OA in 2009 after more than 20 years of direct
clinical care experience. OA’s web-based clinical decision support
system consists of over 2,800 treatment protocols. OA utilizes an expert
team of in-house board certified hematologists and oncologists for peer
review who are supported by a distinguished academic advisory board.
Visit www.oncologyanalytics.com
or call 888-916-2616 to learn more.
About BlueCross BlueShield Venture Partners
BlueCross BlueShield Venture Partners, L.P. is a corporate venture fund
licensed by the Blue Cross and Blue Shield Association, an association
of independent Blue Cross and Blue Shield companies. The fund invests in
promising emerging companies of strategic relevance to Blue Cross and
Blue Shield Plans. Sandbox Industries is the exclusive provider of
investment management services to BlueCross BlueShield Venture Partners.
For more information, please visit www.bcbsvp.com.
Contacts
Oncology Analytics, Inc.
Devon Carlson, 888-916-2616 Ext. 251
dcarlson@oncologyanalytics.com
